Form 4: Milestone Pharmaceuticals Director Andrew Saik Granted Stock Options

Director Andrew Saik of Milestone Pharmaceuticals Inc. was granted stock options to purchase 80,000 common shares on July 15, 2024.

Summary

• Andrew Saik, a director of Milestone Pharmaceuticals Inc., was granted stock options on July 15, 2024.
• The options allow him to purchase 80,000 common shares at an exercise price of $1.585 per share.
• The options vest in equal monthly installments over three years, starting August 15, 2024, contingent on continued service.
• The options expire on July 15, 2034.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a stock option grant. The sentiment is slightly positive as it indicates alignment of director's interests with shareholders.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align management's interests with shareholder value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning the director's interests with the company's success.
• The director is incentivized to increase shareholder value through their work.

Key Dates